Cargando…
Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment
Niemann‐Pick disease type C (NPC) is a rare, genetic, progressive neurodegenerative disorder with high unmet medical need. We investigated the safety and efficacy of arimoclomol, which amplifies the heat shock response to target NPC protein misfolding and improve lysosomal function, in patients with...
Autores principales: | Mengel, Eugen, Patterson, Marc C., Da Riol, Rosalia M., Del Toro, Mireia, Deodato, Federica, Gautschi, Matthias, Grunewald, Stephanie, Grønborg, Sabine, Harmatz, Paul, Héron, Bénédicte, Maier, Esther M., Roubertie, Agathe, Santra, Saikat, Tylki‐Szymanska, Anna, Day, Simon, Andreasen, Anne Katrine, Geist, Marie Aavang, Havnsøe Torp Petersen, Nikolaj, Ingemann, Linda, Hansen, Thomas, Blaettler, Thomas, Kirkegaard, Thomas, í Dali, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293014/ https://www.ncbi.nlm.nih.gov/pubmed/34418116 http://dx.doi.org/10.1002/jimd.12428 |
Ejemplares similares
-
Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study
por: Mengel, Eugen, et al.
Publicado: (2020) -
Correction to: Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study
por: Mengel, Eugen, et al.
Publicado: (2021) -
The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase
por: Fog, Cathrine K., et al.
Publicado: (2018) -
Treatment trials in Niemann-Pick type C disease
por: Sitarska, Dominika, et al.
Publicado: (2021) -
FYCO1 Increase and Effect of Arimoclomol–Treatment in Human VCP–Pathology
por: Guettsches, Anne-Katrin, et al.
Publicado: (2022)